TY - JOUR
T1 - Mitochondrial hyperacetylation in the failing hearts of obese patients mediated partly by a reduction in SIRT3
T2 - The involvement of the mitochondrial permeability transition pore
AU - García-Rivas, Gerardo
AU - Castillo, Elena C.
AU - Morales, José A.
AU - Chapoy-Villanueva, Héctor
AU - Silva-Platas, Christian
AU - Treviño-Saldaña, Niria
AU - Guerrero-Beltrán, C. Enrique
AU - Bernal-Ramírez, Judith
AU - Torres-Quintanilla, Alejandro
AU - García, Noemí
AU - Youker, Keith
AU - Torre-Amione, Guillermo
N1 - Funding Information:
We thank Edgar Acuña, MD for his exceptional technical assistance, Flor Morales, MSc and Andrea Cordero, MD for her help with sample selection. We thank Drs. Leticia Elizondo and Salvador Uribe for their helpful discussion. This work was partially supported by Cardiovascular Medicine Research Group-Tecnológico de Monterrey 0020CAT131 as well as CONACYT-México grants 151136 and 256577 (G. García-Rivas). JAM, NT-S, JB-R and AT-Q were supported by CONACYT graduate scholarships. ECC, HC-V and E G-B were supported by postdoctoral Fellowship (at García-Rivas lab) from CONACYT.
Funding Information:
This work was partially supported by Cardiovascular Medicine Research Group-Tecnológico? de?Monterrey?0020CAT131? as?well?as?CONACYT-México?grants?151136?and? 256577 (G. García-Rivas). JAM, NT-S, JB-R and AT-Q were supported by CONACYT graduate scholarships. ECC, HC-V and E G-B were supported by postdoctoral Fellowship (at García-Rivas lab) from CONACYT.
Publisher Copyright:
© 2019 The Author(s).
PY - 2019
Y1 - 2019
N2 - Background/Aims: Cyclophilin D (CypD) mediates the mitochondrial permeability transition pore (mPTP) opening that contributes to mitochondrial dysfunction. CypD is regulated by its acetylation/deacetylation state that depends on Sirtuin-3 (SIRT3) mitochondrial deacetylase. Since obesity and metabolic syndrome decrease SIRT3 activity and expression, we tested the hypothesis that CypD hyperacetylation promotes mitochondrial dysfunction under this pathophysiological state, which is associated with ventricular dysfunction and heart failure. Methods: Myocardial tissue samples from patients with left ventricular heart failure, with either obesity or normal weight, were processed for the expression of SIRT3 and acetylation profile by Western Blot (WB). In addition, a rat model of obesity and metabolic syndrome induced by 30% (w/v) of sucrose was conducted. The WB analysis was used to determine the levels of mitochondrial expression of SIRT3, Adenine Nucleotide Translocator (ANT), CypD and the acetylation profile, as well as immunoprecipitation to establish the acetylation levels of CypD. Mitochondrial function was assessed by oxygen consumption analysis and maximum Ca2+ retention capacity. Oxidative stress was assessed by aconitase activity, protein carbonyl and thiol groups content. Results: SIRT3 expression in the biopsies of the failing human hearts showed a 46% decrease in the expression levels of obese patients in comparison to the non-obese patients (p=0.0219). Remarkably, body mass index was associated with protein acetylation (0.627; p = 0.035), suggesting that the acetylation profiles of the failing hearts of obese patients are partly mediated by a reduction in SIRT3, which is also associated with higher BNP levels, indicating a more severe ventricular dysfunction (-0.636; p = 0.043). Accordingly, obese rats demonstrated a SIRT3 mitochondrial expression decrease of 22% concomitantly with a hyperacetylated mitochondrial profile, including CypD. Cardiac mitochondria from obese animals were 2.5-fold more prone to mPTP opening than the controls. Conclusion: Our results indicate that obesity reduces SIRT3 expression and that CypD hyperacetylation increases mPTP opening, suggesting that the activation of SIRT3 might be a potential target to decrease ventricular dysfunction and slow the progression of heart failure.
AB - Background/Aims: Cyclophilin D (CypD) mediates the mitochondrial permeability transition pore (mPTP) opening that contributes to mitochondrial dysfunction. CypD is regulated by its acetylation/deacetylation state that depends on Sirtuin-3 (SIRT3) mitochondrial deacetylase. Since obesity and metabolic syndrome decrease SIRT3 activity and expression, we tested the hypothesis that CypD hyperacetylation promotes mitochondrial dysfunction under this pathophysiological state, which is associated with ventricular dysfunction and heart failure. Methods: Myocardial tissue samples from patients with left ventricular heart failure, with either obesity or normal weight, were processed for the expression of SIRT3 and acetylation profile by Western Blot (WB). In addition, a rat model of obesity and metabolic syndrome induced by 30% (w/v) of sucrose was conducted. The WB analysis was used to determine the levels of mitochondrial expression of SIRT3, Adenine Nucleotide Translocator (ANT), CypD and the acetylation profile, as well as immunoprecipitation to establish the acetylation levels of CypD. Mitochondrial function was assessed by oxygen consumption analysis and maximum Ca2+ retention capacity. Oxidative stress was assessed by aconitase activity, protein carbonyl and thiol groups content. Results: SIRT3 expression in the biopsies of the failing human hearts showed a 46% decrease in the expression levels of obese patients in comparison to the non-obese patients (p=0.0219). Remarkably, body mass index was associated with protein acetylation (0.627; p = 0.035), suggesting that the acetylation profiles of the failing hearts of obese patients are partly mediated by a reduction in SIRT3, which is also associated with higher BNP levels, indicating a more severe ventricular dysfunction (-0.636; p = 0.043). Accordingly, obese rats demonstrated a SIRT3 mitochondrial expression decrease of 22% concomitantly with a hyperacetylated mitochondrial profile, including CypD. Cardiac mitochondria from obese animals were 2.5-fold more prone to mPTP opening than the controls. Conclusion: Our results indicate that obesity reduces SIRT3 expression and that CypD hyperacetylation increases mPTP opening, suggesting that the activation of SIRT3 might be a potential target to decrease ventricular dysfunction and slow the progression of heart failure.
KW - Acetylation
KW - Biopsies
KW - Heart failure
KW - Mitochondria
KW - Obesity
KW - Sirtuins
UR - http://www.scopus.com/inward/record.url?scp=85071616564&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071616564&partnerID=8YFLogxK
U2 - 10.33594/000000151
DO - 10.33594/000000151
M3 - Article
C2 - 31464387
AN - SCOPUS:85071616564
SN - 1015-8987
VL - 53
SP - 465
EP - 479
JO - Cellular Physiology and Biochemistry
JF - Cellular Physiology and Biochemistry
IS - 3
ER -